title: Pleuro-pulmonary manifestations of systemic lupus erythematosus: clinical features of its subgroups. Prognostic and therapeutic implications.
abstract: Correct identification of the subsets of pulmonary lupus has an unquestioned importance in planning the proper therapeutic regimen in this extremely variegated disease. Asymptomatic pulmonary lupus needs no treatment; however, pulmonary involvement in lupus may be life threatening, in which case prompt and aggressive treatment is mandatory. The different aspects of pulmonary lupus are demonstrated through the clinical histories of patients who suffered from pleuro-pulmonary lupus. The following entities are presented: lupus pneumonitis, lymphocytic interstitial pneumonia, pulmonary hypertension, pulmonary hemorrhage, pulmonary embolism associated with circulating lupus anticoagulant, lupus pleuritis and weakness of the diaphragm.
mesh_terms: D000328:Adult; D001779:Blood Coagulation Factors / Q000037:antagonists & inhibitors / Q000378:metabolism; D003964:Diaphragm; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications; D008171:Lung Diseases / Q000150:complications*; D016682:Lupus Coagulation Inhibitor; D008180:Lupus Erythematosus, Systemic / Q000145:classification / Q000150:complications* / Q000378:metabolism; D008875:Middle Aged; D009135:Muscular Diseases / Q000150:complications; D010995:Pleural Diseases / Q000150:complications*; D010998:Pleurisy / Q000150:complications; D011655:Pulmonary Embolism / Q000150:complications; D011658:Pulmonary Fibrosis / Q000150:complications; D013902:Radiography, Thoracic
chemical_list: D001779:Blood Coagulation Factors; D016682:Lupus Coagulation Inhibitor